/
/
/

Parmax Pharma Balance Sheet

Consolidated
Standalone
%

Share Price Live Stats

Open (₹)-
Volume (₹)-
High (₹)-
Upper Circuit-
Low (₹)-
Lower Circuit-
Prev Close-
52W High (₹)-
Price-
52W Low (₹)-

Share Market Cap & Key Ratios Overview

M.Cap (₹)-
Div. Yield (%)-
PE Ratio-
Debt to Equity-
Price to Book-
Book Value-
EPS (TTM)-
Face Value-
ROE (%)-

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
CIPLA-ANSE
LAURUSLABS-ANSE
AUROPHARMA-ANSE
DRREDDY-ANSE
LUPIN-ANSE
MANKIND-ANSE
LTP
1W Low
1W High
Market cap (₹)
1842-39.1 (-2.08%)
1833.90
1907.35
4,47,236Cr
9326-244.55 (-2.56%)
9109.80
10000
2,49,673Cr
4975+12.25 (0.25%)
4830
4999
1,87,460Cr
1119.5-30.5 (-2.65%)
1104.05
1167.20
1,11,521Cr
1365-18.95 (-1.37%)
1347.70
1397.05
1,11,484Cr
1970.35+24.85 (1.28%)
1826.95
1981.45
1,04,604Cr
1675.45-10.55 (-0.63%)
1638.65
1703.25
96,031Cr
1161+9.5 (0.83%)
1131.05
1181.40
95,220Cr
2096-16 (-0.76%)
2060.55
2132.45
94,883Cr
2277-28.85 (-1.25%)
2221.10
2330
92,770Cr

Key Highlights of Parmax Pharma Ltd Balance Sheet

Parmax Pharma Ltd balance sheet discloses shareholders' funds of ₹4.45Cr as of 2025-03-31. The company’s equity share capital is at a value of ₹4.45Cr, and the reserves and surplus of the company is -₹6.44Cr.

The company has its non-current liabilities with total liabilities of ₹18.56Cr as of 2025-03-31.

The current liabilities are ₹13.04Cr as of 2025-03-31. At the same time, current assets are ₹10Cr as of 2025-03-31.

Key assets on the balance sheet are non-current investments of ₹40.06Lakh and tangible assets of ₹7.97Cr, provided in the Parmax Pharma Ltd financial statements.